Welcome to our dedicated page for Orexo Ab news (Ticker: ORXOY), a resource for investors and traders seeking the latest updates and insights on Orexo Ab stock.
Orexo AB (ORXOY) is a Swedish pharmaceutical innovator specializing in advanced drug-delivery systems and treatments for opioid use disorder, overdose reversal, and allergic emergencies. This page aggregates official company announcements, clinical trial updates, and strategic financial developments.
Investors and industry professionals will find timely updates on Orexo’s proprietary AmorphOX technology, regulatory milestones, and social bond issuances. Key content includes earnings reports, partnership announcements, patent extensions, and progress on high-priority therapies like OX124 (naloxone) and OX640 (epinephrine).
All updates are sourced directly from Orexo’s communications and verified third-party coverage. Bookmark this page to monitor the company’s progress in addressing critical healthcare challenges through pharmaceutical innovation and sustainable financing strategies.
Orexo will release its Q2 2024 Interim Report on July 17, 2024, at 8 am CET. A presentation for analysts, investors, and media will follow at 2 pm the same day, featuring CEO Nikolaj Sørensen and CFO Fredrik Järrsten. The presentation will cover the latest developments and include a Q&A session. Interested parties can attend either via teleconference or webcast, with registration details and relevant links provided in the press release. Presentation materials will be available on Orexo's website under the Investors/Reports, Presentations section prior to the event.
Orexo AB (ORXOY) has successfully issued senior secured callable floating rate social bonds worth SEK 500 million with a tenor of four years. The company has applied for admission to trading of the bonds on Nasdaq Stockholm after having the listing prospectus approved by the Swedish Financial Supervisory Authority. The estimated first day of trading is around May 14, 2024.
Orexo's Q1 2024 interim report shows positive EBITDA growth, with total net revenues of SEK 139.3 million. The company reported a net earnings improvement, with key data on clinical studies and product stability. Orexo also secured a social bond for refinancing and obtained a new patent. CEO highlights financial stability and R&D progress, aiming for product launch in late 2024 or early 2025.
FAQ
What is the current stock price of Orexo Ab (ORXOY)?
What is the market cap of Orexo Ab (ORXOY)?
